---
document_datetime: 2025-11-24 12:22:36
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/crysvita-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: crysvita-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.2355205
conversion_datetime: 2025-12-25 13:25:50.11042
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## CRYSVITA

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------|----------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| Variation type II /  | This was an application for a group of | 18/09/2025                          | 21/11/2025                                  | SmPC,                            |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000261369   | Labelling and PL   |
|---------------------|--------------------|

<div style=\"page-break-after: always\"></div>

|                                       | of section 4.8 of the SmPC in order to add urticaria to the list of adverse drug reactions (ADRs) with frequency common based on data from clinical trials and post- authorisation data sources; the Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted.                                                                                                                                                                                                                                                                                                |            |            |             |
|---------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|
| Variation type II / EMA/VR/0000280187 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place - Accepted | 04/09/2025 | 21/11/2025 |             |
| Variation type II / EMA/VR/0000246754 | C.I.3 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.b                                                                                                                                                                                                                                                                 | 10/04/2025 | 21/11/2025 | SmPC and PL |

<div style=\"page-break-after: always\"></div>

|                            | Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH - Accepted Update of section 4.6 of the SmPC in order to add a statement on how long contraception should be continued after burosumab treatment has been discontinued, as requested in procedure PSUSA/00010669/202402. The Package Leaflet is updated accordingly.   |
|----------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUR / EMA/PSUR/0000274414 | - -                                                                                                                                                                                                                                                                                                                                                                                            |